Eli Lilly and Company (LLY)
Lilly adds Alzheimer's to online offerings
Eli Lilly on Thursday expanded its direct-to-consumer online platform LillyDirect to include telehealth providers to diagnose and care for patients with Alzheimer's disease, potentially boosting sales of its drug Kisunla.
Eli Lilly, Palo Alto Networks Traders Take Note: Direxion's New Leveraged ETFs Are Here
Active traders have new, highly powered tools at their disposal as Direxion rolls out four single-stock leveraged and inverse exchange-traded funds.
Eli Lilly, Palo Alto Networks Traders Take Note: Direxion's New Leveraged ETFs Are Here
Active traders have new, highly powered tools at their disposal as Direxion rolls out four single-stock leveraged and inverse exchange-traded funds.
2 No-Brainer Growth Stocks to Buy and Hold Forever
Don't let market volatility convince you otherwise: Investing in stocks remains one of the best ways to accumulate capital over long periods. It can be hard to remember that when equities are falling, and the market faces significant uncertainty due to macroeconomic factors -- precisely what we have experienced in 2025.
Eli Lilly (LLY) Stock Sinks As Market Gains: Here's Why
Eli Lilly (LLY) closed at $852.35 in the latest trading session, marking a -1.45% move from the prior day.
Healthy Returns: Novo Nordisk scoops up Chinese obesity drug to compete with Eli Lilly
Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors' perception of the health care system is improving.
Eli Lilly Shares Rise Over 2% After Key Signal
LLY CLIMBS OVER 17 POINTS AT ITS HIGH
Eli Lilly will soon release key data on its weight loss pill. Here's why it could be a game-changer
Eli Lilly plans to release initial results from several late-stage clinical trials on its experimental once-daily obesity pill, orforglipron, this year. The trial results are among the pharmaceutical industry's most critical of the year, as they will bring Eli Lilly's pill one step closer to becoming a new, needle-free alternative for weight loss and diabetes.
Better Stock to Buy Right Now: Viking Therapeutics vs. Eli Lilly
It's hard to overstate how much demand could be out there for effective weight management drugs. The global anti-obesity drug market is expected to generate $12.8 billion in sales this year, and according to a new report from Research and Markets, sales could swell to $104.9 billion by 2035.
Eli Lilly: Growth With Higher Margins
The Eli Lilly and Company investment thesis highlights a robust 2024 performance, driven by a strong pipeline and solid balance sheet, supporting a positive future outlook. The company's strong cash flow and financial health underpin its ability to capitalize on growth opportunities and weather potential risks. Future outlook remains optimistic, with strategic initiatives expected to drive sustained growth and shareholder value.
Lilly's weight-loss drug launch in India to energize rivals eyeing mega market
Eli Lilly on Thursday launched in India its diabetes and weight-loss drug, Mounjaro, which has already clocked in over $20 billion in global sales since its initial U.S. launch in 2022.
5 Reasons It's Not Too Late to Buy Eli Lilly Stock
Eli Lilly (LLY 1.80%) has been around for almost 150 years, finding ways to innovate and grow. Today, it's the most valuable healthcare company in the world, with a market cap of $730 billion.
